Allogeneic Cell Therapy Industry Outlook 2025-2029: Market Set to Cross $1.86 Billion Milestone

Use code ONLINE30 to get 30% off on global market reports and stay ahead of tariff changes, macro trends, and global economic shifts.

How Large Will the Allogeneic Cell Therapy Market Size By 2025?
In recent times, there has been a notable expansion in the market size of allogeneic cell therapy. The market is predicted to surge from $1.08 billion in 2024 to $1.2 billion in 2025, experiencing a compound annual growth rate (CAGR) of 11.9%. This rise during the heritage period can be related to factors such as heightened emphasis on personalizing donor cell selection and genetic adjustments, population growth, escalation in the global incidence of chronic diseases, heightened consciousness, and a rise in partnerships for the development of biosimilars.

How Big Is the Allogeneic Cell Therapy Market Size Expected to Grow by 2029?
Anticipations are high for the allogeneic cell therapy market as it is projected to experience a swift expansion in the upcoming years. It is anticipated to touch $1.86 billion by 2029, with an 11.5% Compound Annual Growth Rate (CAGR). Factors contributing to this predicted surge include a heightened need for sophisticated medical treatments, an escalating demand for innovative allogeneic cell therapies, an increase in clinical trials, a growing patient population, and augmenting income levels. Key trends predicted for the forecast period include technological advancements, collaborations, partnerships among large-scale companies, mergers and acquisitions, as well as new product launches.

View the full report here:
https://www.thebusinessresearchcompany.com/report/allogeneic-cell-therapy-global-market-report

Which Key Market Drivers Powering Allogeneic Cell Therapy Market Expansion and Growth?
The surge in chronic illnesses is anticipated to fuel the expansion of the allogeneic cell therapy market. Chronic illnesses are long-term conditions that generally necessitate continued medical care and can hinder day-to-day activities or life quality. The rise in these illnesses can be attributed to behavioral changes, genetic factors, and exposure to hazardous chemicals, toxins, and air pollutants. Allogeneic cell therapy offers notable promise in the treatment of various chronic diseases by using functional cells from a donor to ameliorate, substitute, or regulate the deficient cells or tissues in the recipient. For instance, the National Center for Biotechnology Information (NCBI), a US-based medical library, reported in January 2023 that the population aged 50 or older suffering from one or more chronic diseases is projected to escalate by 99.5% by 2050, rising from 71.52 million in 2020 to 142.66 million. Hence, the escalating prevalence of chronic diseases propels the expansion of the allogeneic cell therapy market.

Get your free sample here:
https://www.thebusinessresearchcompany.com/sample.aspx?id=15976&type=smp

Which Fast-Growing Trends Are Poised to Disrupt the Allogeneic Cell Therapy Market?
Firms majorly participating in the allogeneic cell therapy market are directing their efforts toward the design of cutting-edge solutions such as cell processing platforms as a means to reinforce their market standing. These platforms comprise systems and techniques utilized to ready cells for therapeutic uses, which includes isolation, purification, expansion, alterations, and quality control to make sure the cells are appropriate for patient treatment. For instance, Getinge, a healthcare firm in Sweden, allied with a British biotechnology entity, CellRev, to introduce Livit ACE, a continual cell processing system (Adherent Cell Expansion) in March 2024. This state-of-the-art platform blends superior automation and bioprocessing technologies substantially amplifying cell production's effectiveness and scalability. Distinctive features encompass advanced cell isolation and purification systems ensuring high cell purity and survival, powerful expansion abilities allowing for the production of large quantity therapeutic cells, refined genetic modification instruments for precise cell engineering, and stringent quality control procedures ensuring the safety and efficiency of the cell products.

What Are the Emerging Segments in the Allogeneic Cell Therapy Market?
The allogeneic cell therapy market covered in this report is segmented -

1) By Type: Stem Cell Therapies, Non-Stem Cell Therapies
2) By Therapeutic Area: Hematological Disorders, Dermatological Disorders, Other Therapeutic Area
3) By End User: Hospitals, Specialty Clinics, Research Organizations

Subsegments:
1) By Stem Cell Therapies: Hematopoietic Stem Cell Therapy (Hematopoietic Stem Cells), Mesenchymal Stem Cell Therapy (MSC-Based Therapies), Induced Pluripotent Stem Cells (iPSC-Based Therapies), Neural Stem Cell Therapy, Other Stem Cell Therapies
2) By Non-Stem Cell Therapies: T-cell Therapies, Natural Killer (NK) Cell Therapies, Dendritic Cell Therapies, Other Non-Stem Cell Therapies

Tailor your insights and customize the full report here:
https://www.thebusinessresearchcompany.com/customise?id=15976&type=smp

Who Are the Global Leaders in the Allogeneic Cell Therapy Market?
Major companies operating in the allogeneic cell therapy market are Novartis AG, Bristol Myers Squibb Company, Takeda Pharmaceutical Company Limited, Bluebird Bio Inc., Poseida Therapeutics Inc., Fate Therapeutics Inc., Fortress Biotech Inc., Sorrento Therapeutics Inc., Eureka Therapeutics Inc., Juno Therapeutics Inc., Adaptimmune Therapeutics plc, Cellectis SA, TrakCel Ltd., Promab Biotechnologies Inc., Ziopharm Oncology Inc., Allogene Therapeutics Inc., Century Therapeutics Inc., Autolus Therapeutics plc, Bellicum Pharmaceuticals Inc., Minerva Biotechnologies Corporation, Celyad SA, TILT Biotherapeutics Ltd., CRISPR Therapeutics AG

Which are the Top Profitable Regional Markets for the Allogeneic Cell Therapy Industry?
North America was the largest region in the allogeneic cell therapy market in 2023. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the allogeneic cell therapy market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Purchase the full report today:
https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=15976

This Report Supports:
1.Business Leaders & Investors - To identify growth opportunities, assess risks, and guide strategic decisions.
2.Manufacturers & Suppliers - To understand market trends, customer demand, and competitive positioning.
3.Policy Makers & Regulators - To track industry developments and align regulatory frameworks.
4.Consultants & Analysts - To support market entry, expansion strategies, and client advisory work.

Connect with us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company,
Twitter: https://twitter.com/tbrc_info,
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ.

Contact Us
Europe: +44 207 1930 708,
Asia: +91 88972 63534,
Americas: +1 315 623 0293 or
Email: mailto:info@tbrc.info

Learn More About The Business Research Company
With over 15,000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Our flagship product, the Global Market Model delivers comprehensive and updated forecasts to support informed decision-making.

This release was published on openPR.